This review assessed the chronic care model for patients with chronic obstructive pulmonary disease and concluded that the inclusion of more than one component benefited hospitalisations, emergency/unscheduled visits and length of stay. However, data were limited and more well-designed trials are needed. The conclusions should be regarded with some caution, mainly due to the absence of consistently demonstrated benefits.
Participants included in the review
Studies in COPD were eligible for inclusion, other than that no inclusion criteria for the participants were specified. The included studies mainly targeted individual patients, some targeted groups and some targeted both groups and individuals.
Outcomes assessed in the review
Studies reporting knowledge, dyspnoea, quality of life, lung function, performance-based tests such as a 6-minute walk test, health care use such as length of hospital stay, clinical end points such as mortality, or costs were eligible.
How were decisions on the relevance of primary studies made?
Two reviewers independently selected studies for inclusion. Any disagreements were resolved by consensus.
Assessment of study quality
Two reviewers independently evaluated the studies in relation to blinding of the outcome assessors. The RCTs were assessed using the U.S. Preventive Services Task Force quality criteria, which cover a variety of pertinent quality issues. Two reviewers independently extracted the data. Information to compute the relative risk (RR) or mean difference was sought.
Data extraction

Methods of synthesis
How were the studies combined? Pooled RRs, weighted mean differences or standardised mean differences were obtained using fixed-effect models and the Mantel-Haenszel (for RR) and DerSimonian and Laird (for mean difference) random-effects models, adjusted for sample size and precisions. The results of the random-effects models were reported, together with the 95% confidence intervals (CIs). Only RCTs with at least 3 studies reporting similar measures were pooled statistically. Publication bias was investigated using funnel plots.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Cochran Q test and the I-squared statistic. An I-squared value of 50% was considered heterogeneous; standardised mean differences instead of weighted mean differences were used in that case.
Results of the review
Thirty-two studies (n approximately 5,527, exact number of participants unclear) were included: 20 RCTs (n approximately 2,948), 5 controlled trials (n=1,478) and 7 before-and-after studies (n=1,101).
Only 1 RCT met all criteria for good quality, 4 trials had one or more methodological problems and were rated 'fair' quality, and 15 of the 20 RCTs had one or more fatal flaw and were rated 'poor' quality. There was no information on the other studies.
Patients that received at least two chronic care interventions had fewer emergency/unscheduled visits (RR 0.58, 95% CI: 0.42, 0.79; 3 RCTs), fewer hospitalisations (RR 0.78, 95% CI: 0.66, 0.94; 4 RCTs) and a shorter hospital stay (weighted mean difference -2.51 days, 95% CI: -3.40, -1.61; 2 RCTs). Only 2 of the 3 pooled studies showed a statistically significant difference for emergency/unscheduled visits. Only 2 of the 4 pooled studies showed a statistically significant reduction in hospitalisations, one showed no statistically significant difference and the other favoured the control group. Statistical heterogeneity was not reported.
The results assessing only one chronic care component intervention showed no clear evidence supporting the intervention groups over the control groups. The results varied also for other assessed outcomes such as lung function, quality of life, functional status and mortality.
